TrialEsophagus : official journal of the Japan Esophageal Society2024

First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.

Ken Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.